Become an ordering provider and offer our tests at your practice.
Register Now
Our blood tests, powered by AI and rooted in epigenetics and genetics, provide actionable insights into heart attack risk and coronary heart disease.
of heart disease is genetic, the majority is driven by lifestyle and environment
heart attacks are silent, occurring
without warning
of suspected ischemia cases reveal no obstructive disease
Epigenetics refers to chemical changes in DNA that reflect an individual's lifestyle or environment. The majority of heart disease risk is acquired from environmental stressors or lifestyle factors, which leave measurable DNA methylation signatures. DNA methylation is a widely studied epigenetic mechanism and can be easily quantified. By analyzing these heart disease-associated signatures, our blood tests uncover molecular signals tied to disease presence and risk.
Our solutions integrate artificial intelligence to interpret complex biological data with precision. Proprietary AI models, trained and validated on independent datasets, detect both hidden and overt disease-associated patterns. This AI-driven approach allows multi-dimensional data, including genetic variation and epigenetic markers, to be translated into clinically actionable insights without losing predictive power. This provides a more comprehensive and individualized understanding of coronary heart disease.
Conventional risk assessments rely on proxy markers such as blood pressure and cholesterol. While these factors may be indicators of heart attack risk, relying on them alone may not be enough. Epi+Gen CHD™ goes deeper, leveraging each patient's unique molecular biology to assess the three-year risk of a coronary heart disease event regardless of the presence or severity of risk factors.
Epi+Gen CHD™ quantifies a patient's three-year risk of coronary heart disease event, including heart attack. Risk is classified as low, borderline, intermediate, or high, and benchmarked against peers of the same sex and similar age.
This clinical blood test is recommended for adults aged 35 to 75 year old, who have not been diagnosed with coronary heart disease, suffered a heart attack, undergone cardiac surgery, has not experienced angina or received a bone marrow transplant.
more sensitive than conventional
risk calculators
Traditional diagnostic methods can fail to identify coronary heart disease in the early stages and lack insight into patient-specific disease drivers. Research has shown that these tests can miss disease in 20-30% of patients, leading to false negatives and delayed treatment. They also frequently overlook Ischemia with No Obstructive Coronary Arteries (INOCA), where patients may experience chest pain and remain at risk despite the absence of significant plaque buildup. PrecisionCHD™ aids in the diagnosis of coronary heart disease, both obstructive and non-obstructive, and maps each patient’s DNA methylation biomarkers to their disease drivers that could be used to help guide treatment.
PrecisionCHD™ detects molecular patterns associated with coronary heart disease. An Actionable Clinical Intelligence™ report, included with this test, gives healthcare providers insights into each patient’s specific molecular disease drivers.
PrecisionCHD™ is recommended for adults aged 35 to 80 years old, who are being evaluated for coronary heart disease and have not had a bone marrow transplant.
Test results include actionable insights on the impact of biomarkers on disease signal and associated pathways to help personalize care
Orders can be submitted online via our Provider Portal or by completing the paper test requisition form included in each sample collection kit.
Sample collection kits are provided at no cost and include all necessary materials for sample collection and shipping. Practices may choose either vacutainer or lancet-style kits and have the option to ship kits directly to patients' homes.
Test results will be available in the Provider Portal within 10 business days of sample receipt at our laboratory.
